1.646.889.1200|info@lifescipublicrelations.com

Alkahest doses first patient in Phase II Parkinson’s drug trial

//Alkahest doses first patient in Phase II Parkinson’s drug trial

Alkahest doses first patient in Phase II Parkinson’s drug trial

Alkahest has dosed the first subject in a Phase II clinical trial of GRF6021 to treat Parkinson’s disease associated with mild cognitive impairment or dementia.

By | 2018-12-06T18:57:24-04:00 December 6th, 2018|News|Comments Off on Alkahest doses first patient in Phase II Parkinson’s drug trial

About the Author:

Related Posts

LifeSci Public Relations

LifeSci Public Relations LLC is a corporate communications and public relations firm helping clients engage their corporate audiences and achieve their business objectives via a broad array of traditional, social and digital media tools.